Radiopharm Theranostics (ASX: RAD) has received approval from the Australian Ethics Committee for the inclusion of additional tumour...

Following publication of its findings in “Frontiers in Nuclear Medicine”, Radiopharm Theranostics (ASX: RAD) revealed a clinical study...

ASX-listed Radiopharm Theranostics (ASX: RAD) has teamed up with US-based BAMF Health to kick off phase 2b trials for its cancer...

ASX-listed Radiopharm Theranostics (ASX: RAD) has joined forces with a renowned global radiopharmaceutical manufacturer to produce its...

Radiopharm Theranostics (ASX: RAD) has moved closer to securing investigational new drug (IND) approval for a cancer-fighting...

Radiopharm Theranostics (ASX: RAD) has boosted its stake in a United States-based joint venture (JV) with the University of Texas MD...

Radiopharm Theranostics (ASX: RAD) has secured the services of United States-based Dr Dimitris Voliotis as its new chief medical officer...

Radiopharm Theranostics (ASX: RAD) has banked US$2 million (AU$3.1 million) from American medical giant Lantheus for the sale of two...

Radiopharm Theranostics (ASX: RAD) has been given the nod of approval by the United States Food and Drug Authority to use its brain...

Radiopharm Theranostics (ASX: RAD) has kicked off the first phase of clinical trials testing its “RAD 204” treatment aimed at beating the...

Radiopharm Theranostics’ (ASX: RAD) stock rocketed up more than 35 per cent this morning after the cancer-fighting firm secured...

Radiopharm Theranostics (ASX: RAD) looks set to fill its coffers with a healthy $18 million following a strategic equity investment and...

The potential for one of Radiopharm Theranostics’ (ASX: RAD) treatments to fight cancer while protecting a patient’s kidneys from...

Radiopharm Theranostics uses a particular isotope of the soft, silvery rare earths metal terbium to treat prostate cancer patients. Credit: File Radiopharm Theranostics says a new six-patient study shows its terbium-based treatment has superior potential to tackle prostate cancer than lutetium following a head-to-head assessment of the rare earths metals in its therapies. Management says the results from tests on patients with metastatic “castrate-resistant” cancer vindicate

Radiopharm Theranostics is conducting a clinical trial to test the safety of its pancreatic cancer treatment. Credit: File Radiopharm Theranostics says it has dosed its first pancreatic cancer patient in the initial phase of a study aimed at providing doctors with an enhanced screening process for the lethal and aggressive disease. The clinical trial in the United States is for the company’s patented “RAD301” radiopharmaceutical technology that is designed to detect lesions i

A Radiopharm Theranostics treatment is presenting new hope in the battle against a wide range of different cancers. Credit: File An immune system protein being developed by Radiopharm Theranostics has for the first time been shown to have the potential to detect and target a specific cellular marker found in a wide range of cancers. The company’s monoclonal antibody known as “DUNP19”, is a first-in-class therapy designed to track down, image and destroy cancer cells in human

Radiopharm increases focus on new lung cancer treatment Credit: File Radiopharm Theranostics is poised to open a second site for conducting human trials of its RAD 204 treatment for advanced non-small cell lung cancer (NSCLC) having received the green light from Perth’s Hollywood Private Hospital Human Research Ethics Committee. The approval comes only a week after the company announced it had taken a step closer to kicking off the trial for patients with NSCLC at its initial

Radiopharm Theranostics is getting close to kicking off a trial for patients with non-small cell lung cancer. Credit: File Radiopharm Theranostics has stepped closer to kicking off what it says could be a “game-changing” trial for patients with non-small cell lung cancer (NSCLC) after a successful initiation site visit to Brisbane’s Princess Alexandra Hospital. The important visit was made ahead of the trial that will evaluate the safety and efficacy of the company’s radiothe

Radiopharm Theranostics create cancer diagnostics and therapies. Credit: File A research and development (R&D) tax rebate of nearly $5 million from the Australian Government will boost Radiopharm Theranostics’ mission to further develop its suite of diagnostic and therapeutic products aimed at beating the cancer scourge. The rebate recognises the company’s R&D activity during the 2023 financial year and comes as it prepares to run clinical pancreatic cancer trials in New York

Radiopharm Theranostics will address an “unmet need” in pancreatic cancer trials. Credit: File Pancreatic cancer patients have been delivered fresh hope following the United States Food and Drug Administration’s decision to clear the way for Melbourne-based Radiopharm Theranostics to run clinical trials in Now York to address an area of “unmet medical need”. The company today revealed the USFDA had accepted its revised investigational new drug (IND) application, allowing it t